NPC1L1 and pachyonychia congenita: Unlike PCSK9, there was no association between the genetically proxied HMG-CoA reductase nor the cholesterol transporter NPC1L1 with reduced PC risk, suggesting the important oncogenic role of PCSK9 in PC [55].